• OPEN AN ACCOUNT
A+| A| A-|
Indian Indices
Sensex
77,409.98 254.36
( 0.33%)
Global Indices
Nasdaq
51,515.27 -505.40
(-0.97%)
Dow Jones
7,441.22 -91.13
(-1.21%)
Hang Seng
71,050.31 1,148.06
(1.64%)
Nikkei 225
10,505.62 11.41
(0.11%)
Forex
USD-INR
94.55 -0.09
(-0.09%)
EUR-INR
109.66 -0.13
(-0.12%)
GBP-INR
126.84 -0.25
(-0.20%)
JPY-INR
0.59 0.00
(-0.20%)

EQUITY - MARKET SCREENER

Standard Shoe Sole & Mould India Ltd
Industry :  Trading
BSE Code
ISIN Demat
Book Value()
523351
INE888N01013
-1.7533533
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
N.A
0
8.77
EPS(TTM)
Face Value()
Div & Yield %
0
10
0
 

Beta Drugs consolidated net profit rises 0.22% in the March 2026 quarter
May 14,2026
Net profit of Beta Drugs rose 0.22% to Rs 9.05 crore in the quarter ended March 2026 as against Rs 9.03 crore during the previous quarter ended March 2025. Sales rose 0.21% to Rs 93.96 crore in the quarter ended March 2026 as against Rs 93.76 crore during the previous quarter ended March 2025.

For the full year,net profit declined 2.22% to Rs 41.48 crore in the year ended March 2026 as against Rs 42.42 crore during the previous year ended March 2025. Sales rose 6.20% to Rs 384.83 crore in the year ended March 2026 as against Rs 362.36 crore during the previous year ended March 2025.

ParticularsQuarter EndedYear Ended
Mar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var.
Sales93.9693.76 0 384.83362.36 6
OPM %18.8218.50 -19.6720.59 -
PBDT16.6318.02 -8 71.5574.05 -3
PBT11.8314.45 -18 54.3961.54 -12
NP9.059.03 0 41.4842.42 -2